Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Emflaza

- PMLiVE

A better direction

Could behavioural science be the key to improving patient outcomes?

- PMLiVE

The Italian Job

Therapy efficacy and value-based reimbursement models

- PMLiVE

US precision medicine push gathers momentum

Hopes to ‘revolutionise’ medicines through creation of shared healthcare databases

- PMLiVE

FDA rejects PTC’s application for muscular dystrophy drug

Says Translarna filing not “sufficiently complete” to permit full review

Eli Lilly HQ

Lilly wins European approval for lung cancer drug Portrazza

First biologic licenced in EU as a first-line treatment for adults with NSCLC

- PMLiVE

The price is right?

To market new innovation against a backdrop of restricted budgets, companies must work hard - and start early

- PMLiVE

US expands recommended use of meningitis B vaccines

Butopts not to back routine use of GSK's Bexsero and Pfizer' Trumenba

ABPI London offices

Pharma must engage on the affordability question, says ABPI

UK pharma trade body says the industry must be willing to discuss drug pricing

The pharma business environment in the US

Tighter regulations, more pricing controls and increased international competition will drive market improvements

- PMLiVE

US clamps down on tax inversion deals

Will make it harder for companies to dodge taxes overseas

- PMLiVE

US talks tough on ‘unpatriotic’ tax inversion deals

Treasury looks to 'meaningfully reduce' tax benefits of such manoeuvres

- PMLiVE

Prosensa says it could file muscular dystrophy drug this year

Drisapersen still shows promise despite GSK’s decision to terminate collaboration

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links